By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Abeona Therapeutics 



Cleveland  Ohio    U.S.A.
Phone: n/a Fax: n/a


SEARCH JOBS


Industry
Biotechnology






Company News
Abeona Therapeutics Announces EB-101 Clinical Update To Be Presented At The Society For Investigative Dermatology Annual Meeting 4/25/2017 1:14:26 PM
Abeona Therapeutics Receives Orphan Drug Designation In The European Union For EB-101 Gene Therapy Clinical Trial For Epidermolysis Bullosa 3/8/2017 8:09:13 AM
Abeona Therapeutics Provides Update From ABO-102 Phase I/II MPS IIIA Clinical Trial At The 13th Annual WORLDSymposium 2017 2/17/2017 8:30:29 AM
Abeona Therapeutics Enrolls First High Dose Subject In Ongoing Phase 1/2 Gene Therapy Clinical Trial In Sanfilippo Syndrome Type A 2/1/2017 7:20:25 AM
Abeona Therapeutics Release: Company Receives Orphan Drug Designation In The European Union For ABO-101 Gene Therapy In Sanfilippo Syndrome Type B 1/19/2017 1:52:02 PM
Abeona Therapeutics Receives Orphan Drug Designation In The European Union For ABO-201 Gene Therapy Program In Juvenile Batten Disease 1/3/2017 10:00:15 AM
Abeona Therapeutics Enrolls First Patient In Phase 2 For EB-101 Gene Therapy Clinical Trial For Epidermolysis Bullosa 9/26/2016 9:51:11 AM
Abeona Therapeutics Completes Enrollment Of Low-Dose Cohort For ABO-102 In Phase 1/2 Clinical Trial For MPS IIIA Patients 8/29/2016 10:27:39 AM
Abeona Therapeutics Doses First Patient In Phase 1/2 Trial With ABO-102 Gene Therapy For Patients With Sanfilippo Syndrome Type A (MPS IIIA) 5/18/2016 9:01:20 AM
Abeona Therapeutics To Present At Source Capital Group's 2016 Disruptive Growth & Healthcare Conference 2/9/2016 10:22:06 AM
12
//-->